Bienaime Jean Jacques's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Dec 6, 2022
- Accession no.
- 0001567619-22-021361
- Filed
- Dec 6, 2022
- Trade date
- Nov 2-Dec 2, 2022
- Filing delay
- 34 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market sales total $156.0K. It was filed 34 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bienaime Jean JacquesCIK 0001221590 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2022 | Common Stock | LLess common codeAcquired | +100 | $86.12 | +$8,612 | 322,924 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −471 | $103.97 | −$48,969.87 | 322,453 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −600 | $103.97 | −$62,382 | 321,853 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −260 | $103.98 | −$27,034.8 | 321,593 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −100 | $104.00 | −$10,400 | 321,493 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −69 | $104.06 | −$7,180.14 | 321,424 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.